SEC Comment Letter for NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545) (SDEV) — Jul 29, 2019
NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545)
Date: July 29, 2019 · CIK: 0001389545 · Accession: 0000000000-19-011702
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-232860
Letter
July 29, 2019 Justin Hall, Esq. Chief Executive Officer NovaBay Pharmaceuticals, Inc. 2000 Powell Street, Suite 1150 Emeryville, CA 94608 Re:NovaBay Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed July 26, 2019 File No. 333-232860 Dear Mr. Hall: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Sonia Bednarowski at 202-551-3666 with any questions. Sincerely, Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
July 29, 2019
Justin Hall, Esq.
Chief Executive Officer
NovaBay Pharmaceuticals, Inc.
2000 Powell Street, Suite 1150
Emeryville, CA 94608
Re:NovaBay Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed July 26, 2019
File No. 333-232860
Dear Mr. Hall:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Sonia Bednarowski at 202-551-3666 with any questions.
Sincerely,
Division of Corporation Finance
Office of Healthcare & Insurance